About Biogenity

Your expression data analysist

The company

Biogenity was founded in the summer of 2018 and is a biotechnology company focusing on expression data analysis for the preclinical-phases.

A need for smarter analysis

The omics technologies are advancing vastly and dominating discovery-based studies for biomarkers. These methods can deliver above 10.000 reading per sample, thus generating a large amount of data, which can be overwhelming for the researcher if not a data-specialist.

Our vision

Biogenity's vision is to make data easy manage and interpret, thus a deeper and more clear understanding of the data is provided - Making advanced data analyzes accessible for all sizes of Enterprises and researchers with one mission: To fuel and focus the search of new biomarkers for disease and better treatments hereof.

Corporate Management

K. Kastaniegaard
Kenneth Kastaniegaard
CEO & Co-Founder

Ph.D. in Biomedical Science and Engineering

Phone: (+45) 71110509
Email: kkas@biogenity.com

L. Loeb
Louis Loeb
CCO & Co-Founder

MSc in Information Technology

Phone: (+45) 71116050
Email: louis@biogenity.com

Our Products

Large parts of our product development are based on our unique pipeline. It can automate much of the process during data analysis by using the right tests for decision making. The programming behind the technology has been developed in-house, but still based on the state of the art biostatistical methods and machine learning.


Powered by The Next Generation Engine

At Biogenity we have developed our own expression engine which we in daily terms call NGen. This powerful engine uses machine learning to sort and analyze your data; making all the right analytical decisions when processing.

The Next Generation Engine allows automating otherwise monotonous and time-consuming tasks when processing expression data. The result hereof is a premium analysis at a low price.

New products in development

We keep optimizing our products to include more types of expression analyzes and make sure the methods used are up-to-date. We strive to ensure our customers to have the best possible understanding of their data to generate their hypotheses and conclusions.


Searching partners for
beta-testing

Using big data for biomarker-validation

We are also developing pipelines to utilize artificial intelligence-based methods to bring big data into personalized medicine. It is our goal to make big data a usable tool for biomarker-validation and discovery accessible for all sizes of Enterprises and researchers.


Become a beta tester

Advisory Board

Advisory Board
Søren Nielsen
CEO at
MetaIQ
Advisory Board
Christian Vinther
Operator at
Qurasense

Business Partners

2A Pharma
Meta IQ

Supporters

Open Entrepreneurship
Innovations Fund Denmark
Aalborg University
Erhvervshus Nordjylland
Aarhus University

Programs and Incubators

SEA
InnoFounder - Graduate
Innovativ Vækst

Subscribe to our Newsletter


Get updates about the development of new data analytic pipelines and new big data-based approached to discover and validate biomarkers, special offers and when we seek partners for new projects.

How often do I get a Newsletter?

We know how annoying overuse of newsletters can be - which is why we only send five a year.


By subscribing you agree to our privacy policy.

Talk with our expert

By requesting you agree to our privacy policy.